Current Research Studies
Cancer - ANBL1531: Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Condition or Therapy:
High-risk neuroblastoma (HR-NBL), ganglioneuroblastoma
Cancer and Blood Disorders
Study Number: ANBL1531
What is the goal of this study?
Researchers want to determine whether the event-free survival rate of high-risk neuroblastoma is improved with the addition of iobenguane I-131 (I-MIBG) during chemotherapy.
Who can join the study?
This study may be a good fit for children and young adults who:
- are 1 to 30 years old, and
- have been newly diagnosed with neuroblastoma or ganglioneuroblastoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.